We are particularly interested in LRRK1 because LRRK1 is an ideal drug target, and partial inhibition of the LRRK1 function with small molecular inhibitors is assumed to enhance bone density and strength for the treatment of osteoporosis. The gene discussed is LRRK1; the disease is osteoporosis.